<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR l5(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended June 29, 1996
Commission file number 0-19882
KOPIN CORPORATION
-----------------
(Exact name of registrant as specified in its charter)
DELAWARE 04-2833935
-------- ----------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
695 MYLES STANDISH BLVD.,TAUNTON, MA 02780-1042
------------------------------------ ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (508) 824-6696
--------------
Not Applicable
--------------
Former name, former address, and former fiscal year, if changed since last
report
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or l5(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes X No __
---
Applicable only to corporate issuers:
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
Class Outstanding as of July 31, 1996
----- -------------------------------
Common Stock, par value $ .01 10,919,207
<PAGE>
KOPIN CORPORATION
INDEX
-----
Page No.
-------
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Balance Sheets at 3
June 29, 1996 and December 31, 1995
Consolidated Statements of Operations for the 4
Three and six months ended June 29, 1996 and
July 1, 1995
Consolidated Statements of Stockholders' Equity
for the Six months ended June 29, 1996 and
July 1, 1995 5
Consolidated Statements of Cash Flows for the 6
Six months ended June 29, 1996 and July 1, 1995
Notes to Consolidated Financial Statements 7
Item 2. Management's Discussion and Analysis of
Financial Condition 9 and Results of Operations 9
PART II - OTHER INFORMATION
Item 4. Submission of Matters to a Vote of
Security-Holders 12
Item 6. Exhibits and Reports on Form 8-K 12
SIGNATURES 13
2
<PAGE>
KOPIN CORPORATION
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
<TABLE>
<CAPTION>
June 29, 1996 December 31, 1995
-------------- -----------------
<S> <C> <C>
ASSETS
- ---------------------------
Current assets:
Cash and equivalents $18,735,343 $ 24,718,023
Marketable securities 13,288,442 17,278,954
Accounts receivable, net of
allowance of $109,600 and
$85,600
Billed 4,899,854 3,147,846
Unbilled 3,255,681 3,438,766
Inventory 6,851,140 6,402,190
Prepaid expenses and
other current assets 1,374,502 1,984,612
------------ -------------
Total current assets 48,404,962 56,970,391
Equipment and improvements:
Equipment 19,386,479 19,258,354
Leasehold improvements 840,814 835,900
Furniture and fixtures 426,816 414,707
Equipment under
construction 1,358,657 964,446
------------ -------------
22,012,766 21,473,407
Accumulated depreciation
and amortization 10,634,744 9,902,444
------------ -------------
11,378,022 11,570,963
Other assets 3,167,241 3,438,334
Intangible assets 2,903,102 4,179,877
------------ -------------
Total assets $65,853,327 $ 76,159,565
============ =============
LIABILITIES AND
STOCKHOLDERS' EQUITY
- ---------------------------
Current liabilities:
Notes payable $ 500,000 $ 3,000,000
Accounts payable 9,999,737 7,712,508
Accrued payroll
and expenses 1,288,719 808,826
Current portion of
long-term obligations 980,179 629,643
Current portion of
unearned revenue 92,004 92,004
------------ -------------
Total current
liabilities 12,860,639 12,242,981
Deferred rent 405,833 388,833
Unearned revenue, less
current portion 34,482 80,484
Long-term obligations,
less current portion 2,291,898 1,605,050
Minority interest 929,925 -
Stockholders' equity:
Preferred stock, par
value $.01 per share:
Authorized, 3,000 shares;
none issued and
outstanding
Common stock, par value
$.01 per share:
Authorized, 20,000,000
shares;
issued 10,918,832 shares
in 1996 and 10,915,019
shares in 1995 109,188 109,150
Additional paid-in capital 88,362,132 88,355,145
Deferred compensation (71,094) (94,482)
Marketable securities
valuation 209,195 137,183
Accumulated deficit (39,278,871) (26,664,779)
------------- ------------
Total stockholders'
equity 49,330,550 61,842,217
------------ -------------
Total liabilities and
stockholders' equity $65,853,327 $ 76,159,565
============ =============
</TABLE>
See notes to consolidated financial statements.
3
<PAGE>
KOPIN CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
Three Months Ended Six Months Ended
------------------ ----------------
June 29 July 1 June 29 July 1
1996 1995 1996 1995
-------------- -------------- --------------- -------------
<S> <C> <C> <C> <C>
Revenue:
Product sales $ 2,582,490 $ 1,018,082 $ 5,626,256 $ 1,601,657
Research and development 1,695,900 2,341,146 3,425,372 4,316,292
Interest and other income 445,785 466,351 1,006,181 912,322
------------- ------------- -------------- ------------
4,724,175 3,825,579 10,057,809 6,830,271
------------- ------------- -------------- ------------
Costs and expenses:
Cost of sales 2,225,152 862,768 4,933,070 1,406,726
Research and development 4,492,359 4,224,977 9,203,328 8,336,649
General, administrative and selling 1,966,955 848,735 3,910,611 1,574,596
Interest 93,309 99,150 217,518 153,681
Other 152,268 64,713 287,037 133,266
Non-recurring charge -- -- 4,990,412 --
------------- ------------- -------------- ------------
8,930,043 6,100,343 23,541,976 11,604,918
------------- ------------- -------------- ------------
Loss before minority interest (4,205,868) (2,274,764) (13,484,167) ( 4,774,647)
Minority interest in loss of subsidiary 312,829 -- 870,075 --
------------- ------------- -------------- ------------
Net loss ($ 3,893,039) ($ 2,274,764) ($ 12,614,092) ($4,774,647)
============= ============= ============== ============
Net loss per share ($ .36) ($ .24) ($ 1.16) ($ .51)
============= ============= ============== ============
Weighted average number of common
shares outstanding 10,918,750 9,301,763 10,917,304 9,300,361
============= ============= ============== ============
</TABLE>
See notes to consolidated financial statements.
4
<PAGE>
KOPIN CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
SIX MONTHS ENDED JUNE 29, 1996 AND JULY 1, 1995
(UNAUDITED)
<TABLE>
<CAPTION>
Additional
Common Stock Paid-in Deferred Securities
---------- --------
Shares Amount Capital Compensation Valuation Deficit Total
---------- -------- ----------- ------------- ----------- ------------- -----------
<S> <C> <C> <C> <C> <C> <C> <C>
Balance, December 31, 1994 9,298,711 $ 92,987 $61,926,736 ($224,670) ($670,000) ($17,673,780) $ 43,451,273
Exercise of stock options 4,750 48 4,703 -- -- -- 4,751
Amortization of compensation
relating to grant of stock options -- -- -- 65,094 -- -- 65,094
Net unrealized gain on marketable
securities -- -- -- -- 420,000 -- 420,000
Net loss for the six month
period ended July 1, 1995 -- -- -- -- -- (4,774,647) (4,774,647)
---------- -------- ----------- ------------ ---------- ------------ ------------
Balance, July 1, 1995 9,303,461 $ 93,035 $61,931,439 ($ 159,576) ($250,000) ($22,448,427) $ 39,166,471
========== ======== =========== ============ ========== ============ ============
Balance, December 31, 1995 10,915,019 $109,150 $88,355,145 ($94,482) $ 137,183 ($26,664,779) $ 61,842,217
Exercise of stock options 3,813 38 6,987 -- -- -- 7,025
Amortization of compensation
relating to grant of stock options -- -- -- 23,388 -- -- 23,388
Net unrealized gain on marketable
securities -- -- -- -- 72,012 -- 72,012
Net loss for the six month
period ended June 29, 1996 -- -- -- -- -- (12,614,092) (12,614,092)
---------- -------- ----------- ------------ ---------- ------------ ------------
Balance, June 29, 1996 10,918,832 $109,188 $88,362,132 ($ 71,094) $ 209,195 ($39,278,871) $ 49,330,550
========== ======== =========== ============ ========== ============ ============
</TABLE>
See notes to consolidated financial statements.
5
<PAGE>
KOPIN CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
<TABLE>
<CAPTION>
Six Months Ended
June 29 July 1
1996 1995
-------------- --------------
<S> <C> <C>
Cash flows from operating activities:
Net loss ($12,614,092) ($ 4,774,647)
Adjustments to reconcile net loss
to net cash used in operating
activities:
Depreciation and amortization 1,796,893 1,422,306
Amortization of compensation
relating to grant
of stock options 23,388 65,094
Non-recurring charge 4,990,412 -
Loss on equity investment - 411,181
Decrease in unearned revenue (46,002) (46,002)
Increase in accrued rent 17,000 17,001
Minority interest in loss of (870,075) -
subsidiary
Changes in assets and liabilities:
Accounts receivable (1,568,923) (316,286)
Inventory (448,950) (586,555)
Prepaid expenses and other (243,257) (499,500)
current assets
Intangible assets (1,455,500) (151,815)
Accounts payable and accrued 1,867,122 1,252,946
expenses ------------- -------------
Net cash used in operating (8,551,984) (3,206,277)
activities ------------- -------------
Cash flows from investing activities:
Acquisition of Forte Technologies,
Inc., net of
cash acquired - (1,284,358)
Marketable securities 4,062,524 2,380,320
Other assets 271,093 (815,569)
Capital expenditures (2,108,722) (1,505,612)
------------- -------------
Net cash provided by (used in) 2,224,895 (1,225,219)
investing activities ------------- -------------
Cash flows from financing activities:
Net proceeds from issuance of
subsidiary preferred stock 1,800,000 -
Proceeds from notes payable 500,000 3,000,000
Principal payment on notes payable (3,000,000) -
Proceeds from long-term obligations 1,503,025 -
Principal payment on long-term (465,641) (298,680)
obligations
Proceeds from exercise of stock 7,025 4,751
options ------------- -------------
Net cash provided by financing 344,409 2,706,071
activities ------------- -------------
Net decrease in cash and equivalents (5,982,680) (1,725,425)
Cash and equivalents, beginning of 24,718,023 1,887,271
period ------------- -------------
Cash and equivalents, end of period $ 18,735,343 $ 161,846
============= =============
Non-cash investing and financing
transactions:
Marketable securities valuation $ 72,012 $ 420,000
Supplementary information -Interest $ 177,136 $ 168,987
paid in cash
</TABLE>
See notes to consolidated financial statements.
6
<PAGE>
KOPIN CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. BASIS OF PRESENTATION
---------------------
The financial statements for the six month periods ended June 29, 1996 and July
1, 1995 are unaudited and include all adjustments which, in the opinion of
management, are necessary to present fairly the results of operations for the
periods then ended. All such adjustments are of a normal recurring nature. These
financial statements should be read in conjunction with the financial statements
and notes thereto included in the Company's Annual Report on Form 10-K filed
with the Securities and Exchange Commission (File No. 0-19882) for the year
ended December 31, 1995.
The results of the Company's operations for any interim period are not
necessarily indicative of the results of the Company's operations for any other
interim period or for a full fiscal year. Certain reclassifications have been
made to be in conformity with the current year presentation.
The consolidated financial statements include the accounts of the Company and
its wholly-owned and majority-owned subsidiaries. All intercompany transactions
and balances have been eliminated. In 1994, the Company made equity investments
in Forte Technologies, Inc. In May 1995, the Company obtained a controlling
interest in Forte and has consolidated the financial statements of Forte with
those of the Company since that date.
2. NET LOSS PER SHARE
------------------
Net loss per share is computed using the weighted average number of common
shares outstanding during the period. Common share equivalents have not been
included because the effect would be anti-dilutive.
3. INVESTMENT IN FORTE TECHNOLOGIES, INC. AND MINORITY INTEREST
------------------------------------------------------------
In October 1994, Kopin acquired a 31% equity interest in Forte Technologies,
Inc., a developer and manufacturer of virtual reality head-mounted systems.
During 1995, Kopin made a series of additional equity investments in and loans
to Forte which resulted in an aggregate equity investment totaling $4,750,000
and loans outstanding of $1,750,000 at December 31, 1995.
In January 1996, Kopin converted a $1,000,000 loan outstanding to Forte as part
of a $2,800,000 private equity offering of Forte common stock. Net proceeds to
Forte totaled $1,800,000 from minority investors. Additionally, in January
1996, Kopin guaranteed an aggregate of $1,000,000 of equipment and working
capital loans obtained by Forte from a senior lender and agreed to subordinate
its remaining $750,000 loan to Forte to the equipment and working capital loans.
In June 1996, Kopin entered into a subordinated debt agreement with Forte as
part of a $2,118,000 subordinated debt financing pursuant to which Kopin
purchased as part of the initial closing $841,837 of subordinated notes and
warrants. At June 29, 1996, Kopin held a 59% equity ownership in Forte.
4. NOTE PAYABLE AND LONG-TERM OBLIGATIONS
--------------------------------------
In 1995, the Company entered into a $3,000,000 demand note agreement with a bank
which bears interest at 1/2% above prime. In May 1996, the note was repaid in
full.
During the three months ended March 30, 1996, the Company entered into two
separate equipment financing agreements totaling approximately $1,286,000 as
well as a $500,000 demand note agreement.
7
<PAGE>
5. NON-RECURRING CHARGE
--------------------
On January 1, 1996 , the Company adopted SFAS No. 121, "Accounting for the
Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed Of ." This
Statement establishes accounting standards for the carrying value of long-lived
and certain identifiable intangible assets. In January 1996, the Company
incurred a non-recurring charge of $4,990,412 which included a write-down
associated with the initial adoption of SFAS No.121, the expensing of purchased
technology, and the write-off of certain previously deferred expenses.
6. RECENT PRONOUNCEMENTS
---------------------
In October 1995, the Financial Accounting Standards Board issued SFAS No. 123,
"Accounting for Stock-Based Compensation," which was effective for the Company
beginning January 1, 1996. SFAS No.123 requires expanded disclosures of stock-
based compensation arrangements with employees and encourages (but does not
require) compensation costs to be measured based upon the fair value of the
equity instrument awarded. However, companies are permitted to continue to apply
APB Opinion No. 25, which recognizes compensation cost based on the intrinsic
value of the equity instrument awarded. The Company will continue to apply APB
Opinion No. 25 to its stock based compensation awards to employees and will
disclose the required pro forma effect on net income and earnings per share in
the Company's year ended December 31, 1996 financial statements.
8
<PAGE>
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
---------------------------------------------------------------
RESULTS OF OPERATIONS
---------------------
Kopin Corporation and its subsidiaries ("the Company") are engaged in the
development, manufacture and sale of flat panel display devices and
products, and custom wafer-engineered electronic materials for commercial
and consumer markets. To date, the Company's revenue has been derived
primarily from development contracts with commercial companies and
agencies of the federal government, as well as from sales of its custom
wafer-engineered materials and flat panel display devices and products.
RESULTS OF OPERATIONS
The Company's research and development and product sale revenue
was $4,278,390 and $9,051,628 during the three and six months ended June
29, 1996 compared to $3,359,228 and $5,917,949 earned during the
corresponding periods in the prior year, an increase of $919,162 or 27%
for the three months and $3,133,679 or 53% for the six months ended June
29, 1996. Research and development revenue decreased 28% to $1,695,900 for
the three months ended June 29, 1996 from $2,341,146 in the prior year and
decreased 21% to $3,425,372 for the six months ended June 29, 1996 from
$4,316,292 in the prior year. The change in 1996 research and development
revenue was primarily attributable to a decrease in contract revenue from
agencies of the federal government. The Company's product sales increased
154% to $2,582,490 during the three months ended June 29, 1996 from
$1,018,082 in the prior year and increased 251% to $5,626,256 for the six
months ended June 29, 1996 from $1,601,657 during the corresponding period
in the prior year. The sales increase was primarily due to initial sales
of the Company's head-mounted display products and an increase in unit
sales of the Company's wafer-engineered materials. The increase in unit
sales of the Company's wafer-engineered materials is primarily due to the
increase in demand for these materials for use in various wireless
telecommunications products.
Interest and other income was $445,785 and $1,006,181 for the
three and six months ended June 29, 1996 compared to $466,351 and $912,322
during the corresponding period in 1995. The changes in 1996 from the
corresponding periods in the prior year reflect higher cash balances with
shorter durations of maturity.
The Company's total operating expenses were $8,930,043 for the
three months ended June 29, 1996 and $23,541,976 for the six months then
ended compared to $6,100,343 and $11,604,918 for the same periods in the
prior year. The increase of $2,829,700 or 46% for the three months ended
June 29, 1996 and $11,937,058 or 103% for the six months then ended was
primarily due to the increase in cost of sales associated with higher
sales volume of wafer-engineered materials and display products, increased
costs incurred for internal development programs, personnel increases and
increased sales and marketing costs for the Company's head-mounted display
products. Additionally, the six months ended June 29, 1996 included an
increase of $4,990,412 related to a non-recurring charge for the write-
down of certain intangible and long-lived assets in connection with the
Company's adoption of the provisions of Statement of Financial Accounting
Standards No. 121, the expensing of purchased technology, and the write-
off of certain previously deferred expenses. Cost of sales, which is
comprised of materials, labor and manufacturing overhead, were
approximately 86% and 88% of product sales for the three and six months
ended June 29, 1996, respectively, compared to approximately 85% and 88%
of product sales for the corresponding periods in the prior year. Reducing
cost of sales as a percentage of sales for the Company's products is
generally dependent on achieving manufacturing economies of scale in order
to manufacture at a lower per unit basis.
Research and development expenses include expenses incurred in
support of internal development programs and programs funded by agencies
of the federal government. Total research and development expenses for the
three and six months ended June 29, 1996 were $4,492,359 and $9,203,328
compared to $4,224,977 and $8,336,649 during the corresponding periods in
1995. The increases of $267,382 or 6% for the three months and $866,679 or
10% for the six months then ended were primarily due to increased activity
in the Company's internal development programs for electronic imaging
devices and display products, wafer-engineered materials and head-mounted
display systems, including increases in circuit design costs, staffing,
purchases of materials and laboratory supplies, subcontractor development
work, and fabrication and packaging of the Company's SMART SLIDE imaging
devices. These increases were partially offset by a reduction in research
and development expenses incurred in support of programs funded by
agencies of the federal government.
9
<PAGE>
General, administrative and selling expenses consist of the
expenses incurred by the Company's business development and sales
personnel, marketing expenses, and administrative and general corporate
expenses. General, administrative and selling expenses were $1,966,955 and
$3,910,611 for the three and six months ended June 29, 1996, compared to
$848,735 and $1,574,596 for the corresponding periods in the prior year.
The increase in general, administrative and selling expenses in 1996 was
primarily due to increases in display product marketing costs, advertising
and trade show costs, as well as increased personnel and related costs.
In addition, general and administrative expenses include non-cash charges
for compensation expense of $11,694 and $23,388 for the three and six
months ended June 29, 1996, relating to the issuance of certain stock
options. The Company expects to incur additional increases in general,
administrative and selling expenses in the future as it commercializes its
imaging devices and display products.
During 1995, the Company adopted SFAS No. 107, "Disclosure About
Fair Value of Financial Instruments," effective January 1, 1995, as
required. The effect of this adoption had no material impact on the
Company's financial statements.
On January 1, 1996 , the Company adopted SFAS No. 121,
"Accounting for the Impairment of Long-Lived Assets and Long-Lived Assets
to be Disposed Of ." This Statement establishes accounting standards for
the carrying value of long-lived and certain identifiable intangible
assets. In January 1996, the Company incurred a non-recurring charge of
$4,990,412 which included a write-down associated with the initial
adoption of SFAS No.121, the expensing of purchased technology, and the
write-off of certain previously deferred expenses.
In October 1995, the Financial Accounting Standards Board issued
SFAS No. 123, "Accounting for Stock-Based Compensation," which was
effective for the Company beginning January 1, 1996. SFAS No.123 requires
expanded disclosures of stock-based compensation arrangements with
employees and encourages (but does not require) compensation costs to be
measured based upon the fair value of the equity instrument awarded.
However, companies are permitted to continue to apply APB Opinion No. 25,
which recognizes compensation cost based on the intrinsic value of the
equity instrument awarded. The Company will continue to apply APB Opinion
No. 25 to its stock based compensation awards to employees and will
disclose the required pro forma effect on net income and earnings per
share in the Company's year ended December 31, 1996 financial statements.
LIQUIDITY AND CAPITAL RESOURCES
The Company has financed its operations primarily through private
placements of its equity securities, the initial public offering of its
common stock in April 1992, another public offering in March 1993,
research and development revenue, and sales of its custom wafer-engineered
materials and flat panel display devices and products. The Company has an
unused line of credit of $500,000 at June 29, 1996. The Company
periodically enters into loan agreements to finance equipment purchases
and other activities. As of June 29, 1996, sales of equity securities have
raised approximately $92,500,000, including $13,300,000 of net proceeds
from the Company's initial public offering, $26,500,000 of net proceeds
from the Company's March 1993 public offering, $3,300,000 from a private
stock sale in November 1992, $4,375,000 from the exercise of a 625,000
share stock warrant in December 1993, and $30,437,000 from private stock
sales to Telecom Holding Co., Ltd. and United Microelectronics Corporation
and its affiliate in the fourth quarter of 1995.
As of June 29, 1996, the Company had cash and equivalents and
marketable securities of $32,023,785 and working capital of $35,544,323
compared to $41,996,977 and $44,727,410 as of December 31, 1995. The
decrease in cash and equivalents and marketable securities is primarily
due to $8,551,984 of cash used in operations and $2,108,722 for capital
expenditures. These decreases were partially offset by borrowings of
$1,503,025 and $1,800,000 in equity financing raised by one of the
Company's subsidiaries from certain of its minority stockholders. The
Company also has approximately $1,954,000 of marketable securities held in
escrow as equipment financing collateral which is shown in other assets.
Revenue from long-term contracts is recognized on the percentage-
of-completion method of accounting as work is performed, based upon the
ratio that incurred costs or hours bear to estimated total completion
costs or hours. Amounts received under long-term contracts are recognized
as revenue is earned, and amounts earned on contracts in progress in
excess of billings are classified as unbilled receivables. Unbilled
receivables are billed based on dates stipulated in the related agreement
or in periodic installments based upon the Company's invoicing cycle.
10
<PAGE>
The Company periodically enters into various long-term debt
arrangements in connection with acquisition of certain capital equipment.
During the six months ended June 29, 1996, the Company entered into two
separate equipment financing agreements and a subordinated debt agreement
totaling $1,503,025. As of June 29, 1996, total long-term debt obligations
totaled $3,272,077, of which $980,179 is payable in 1996. Additionally, in
January 1996, the Company entered into a $500,000 demand note agreement.
In October 1993, the Company entered into a five-year lease for a
74,000 square foot manufacturing facility. This facility, which includes
7,000 square feet of environmentally controlled clean rooms, is being used
for expansion of the Company's manufacturing capabilities for production
of wafer-engineered materials and electronic imaging devices. The Company
will make lease payments of approximately $4.0 million over the five-year
term.
The Company expects to expend approximately $8,000,000 over the
next 36 months on equipment primarily related to development and
manufacturing of electronic imaging devices and display products and
wafer-engineered electronic materials. Of this amount, the Company expects
to use approximately $3,000,000 in 1996, $3,000,000 in 1997, and
$2,000,000 in 1998 for capital equipment and expansion of the Company's
manufacturing capabilities. Of these amounts, approximately $6,000,000 is
expected to be used for expansion of manufacturing equipment required for
development and manufacturing of electronic imaging devices and display
products, and wafer-engineered materials, and the balance is expected to
be used for the acquisition of laboratory and testing equipment and
general facility upgrades. The Company also expects to use approximately
$3,000,000 for development of advanced display circuit designs for its
electronic imaging devices.
The Company expects to incur significant additional research and
development and other costs, including costs related to the development
and commercialization of its electronic imaging devices and display
products. The Company's future capital requirements will depend on many
factors involving risks and uncertainties, including the establishment of
collaborative arrangements, the cost of manufacturing facilities,
commercialization activities and arrangements, continued scientific
progress in its imaging device and display product development programs,
the magnitude of these programs, the costs involved in filing, prosecuting
and enforcing patent claims, and competing technological and market
developments.
In October 1994, the Company made an equity investment of
$1,000,000 in Forte Technologies, Inc., a developer and manufacturer of
virtual reality head-mounted systems. Subsequently, the Company has made a
series of additional equity investments in Forte totaling $4,750,000,
increasing its equity ownership to 59% at June 29, 1996. From time to
time, Kopin may make equity and nonequity investments in other companies,
including Forte, engaged in certain aspects of the flat panel display and
electronics industries as part of its business strategy.
The Company believes that its present cash and equivalents and
marketable securities will be adequate to finance its anticipated
operating and capital requirements and to meet liquidity needs through at
least fiscal 1997.
FUTURE OPERATING RESULTS
Certain of the statements contained in this Form 10-Q, including
Management's Discussion and Analysis of Financial Condition and Results of
Operations, are forward-looking statements that involve risks and
uncertainties. In addition to the risks and uncertainties set forth in
this Form 10-Q, other factors that could cause actual results to differ
materially include the following: general economic and business conditions
and growth in the flat panel display industry, the impact of competitive
products and pricing, availability of third party components, availability
of integrated circuit fabrication facilities, cost and yields associated
with production of the Company's SMART SLIDE imaging devices, and the risk
factors listed from time to time in the Company's periodic reports filed
with the Securities and Exchange Commission, including but not limited to
the Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 1995.
11
<PAGE>
PART II. OTHER INFORMATION
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY-HOLDERS
On May 23, 1996, the Company held its Annual Meeting of Stockholders to consider
and vote upon the following three proposals:
(1) A proposal to elect (8) directors of the Company to serve until the
next Annual of Meeting of Stockholders and until their successors are
duly elected and qualified.
(2) A proposal to ratify the amendment to the Company's 1992 Stock Option
Plan increasing the number of shares authorized for issuance under
the Plan.
(3) A proposal to ratify the appointment of Deloitte & Touche LLP as
independent accountants of the Company for the current fiscal year.
Results with respect to the voting on each of the proposals were as follows:
<TABLE>
<CAPTION>
For Withheld Authority
------- -------------------
<S> <C> <C>
Proposal 1:
John C.C. Fan 9,312,882 226,180
David E. Brook 9,312,882 226,180
Andrew H. Chapman 9,312,882 226,180
Morton Collins 9,312,882 226,180
Anthony B. Evnin 9,312,882 226,180
Chi Chia Hsieh 9,313,282 225,780
Michael A. Wall 9,312,882 226,180
Vallobh Vimolvanich 9,313,282 225,780
</TABLE>
Proposal 2: 5,635,673 votes for; 931,847 votes against:46,228 abstentions;
and 2,925,314 broker non-votes.
Proposal 3: 9,448,709 votes for; 53,858 votes against; and 36,495 abstentions
Item 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
10.3 Amendment to 1992 Stock Option Plan
10.53 Securities Purchase Agreement, by and between Forte Technologies,
Inc. and Investors, dated June 27, 1996.
27 Financial Data Schedule
(b) Reports on Form 8-K
none
12
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KOPIN CORPORATION
(Registrant)
Date: August 10, 1996 By: /s/ John C.C. Fan
--------------------------------------
President, Chief Executive Officer
and Chairman of the Board of Directors
(Principal Executive Officer)
Date: August 10, 1996 By: /s/ Paul J. Mitchell
------------------------------------
Paul J. Mitchell
Treasurer and Chief Financial Officer
(Principal Financial and Accounting
Officer)
13
<PAGE>
KOPIN CORPORATION
1992 STOCK OPTION PLAN
AMENDMENT
Kopin Corporation (the "Company"), pursuant to authority reserved in
Section 18 of the 1992 Stock Option Plan, as amended, of the Company (the "1992
Plan"), hereby amends the 1992 Plan, subject to Shareholder approval within one
year of the date hereof, as follows:
Effective as of February 15, 1996, the date of the adoption by the Board of
Directors of the Company of the Amendment provided hereby, the first sentence of
Section 5 of the 1992 Plan is deleted in its entirety and is replaced with the
following:
"The Plan covers 2,350,000 shares of Stock; provided, that the number
--------
of shares purchased pursuant to the exercise of Options granted under the
Plan and options granted under the Old Plan and the number of shares
---
subject to outstanding Options granted under the Plan and options granted
under the Old Plan shall be charged against the shares covered by the Plan;
but shares subject to Options granted under the Plan or options granted
under the Old Plan which terminated without being exercised shall not be so
charged."
IN WITNESS WHEREOF, the Company has adopted this Amendment as of the 15/th/ day
of February, 1996 to be effective as hereinabove provided.
KOPIN CORPORATION
By:_________________________________
John C.C. Fan, Chief Executive Officer
The following does not form part of this Amendment but is included solely for
information purposes:
Date of Board Approval: February 15, 1996
Date of Shareholder Approval: May 23, 1996
<PAGE>
SECURITIES PURCHASE AGREEMENT
BY AND BETWEEN
FORTE TECHNOLOGIES, INC.
THE COMPANY
-------
AND
THE INVESTORS
---------
LISTED ON SCHEDULE 1 HERETO
---------------------------
DATED AS OF JUNE 27, 1996
<PAGE>
Forte Technologies, Inc.
SECURITIES PURCHASE AGREEMENT
June 27, 1996
To each of the Investors
(as hereinafter defined)
Gentlemen:
The undersigned, Forte Technologies, Inc., a New York corporation (the
"Company"), hereby agrees with each of the persons listed on Schedule 1 hereto
----------
(as the same may be amended from time to time as herein provided) (each an
"Investor" and, collectively, the "Investors") as follows:
1. DEFINITIONS. Certain terms are used in this Agreement as specifically
defined in Exhibit 1 hereto.
------- -
2. THE SUBORDINATED NOTES AND WARRANTS. The Company has, or will have
prior to the Stage 1 Closing Date, duly authorized the following:
2.1. The issuance and sale to the Investors on the Stage 1 Closing
Date of (i) subordinated notes in the aggregate principal amount of $1,059,000,
with a maturity of five (5) years and bearing interest at an annual rate of 3%
(the "Stage 1 Subordinated Notes") and (ii) warrants to purchase up to an
aggregate number of 1,059,000 shares of common stock of the Company, par value
$.10 per share (the "Common Stock") at an exercise price of $.10 per share (the
"Stage 1 Warrants").
2.2. The issuance and sale to the Investors on the Stage 2 Closing
Date of (i) subordinated notes in the aggregate principal amount of $1,059,000,
with a maturity of five (5) years and bearing interest at an annual rate of 3%
(the "Stage 2 Subordinated Notes" and together with the Stage 1 Subordinated
Notes, the "Subordinated Notes") and (ii) warrants to purchase up to an
aggregate number of 1,059,000 shares of common stock of the Company, par value
$.10 per share (the "Common Stock") at an exercise price of $.10 per share (the
"Stage 2 Warrants" and together with the Stage 1 Warrants, the "Warrants").
3. SALE AND PURCHASE OF SUBORDINATED NOTES AND WARRANTS.
3.1. AGREEMENT TO SELL AND PURCHASE THE SUBORDINATED NOTES AND WARRANTS. The
----------------------------------------------- ----- --- --------
Company is selling to each Investor, and each Investor is purchasing from the
Company, the following:
<PAGE>
-2-
(a) Subject to the satisfaction of the conditions precedent set forth
in Sections 6.1 and 6.2 hereof and subject to the terms and other conditions
hereinafter set forth, at the Stage I Closing, the respective amount of Stage I
Subordinated Notes and Stage 1 Warrants set forth on Schedule 1 for an aggregate
----------
purchase price of $1,059,000 for the Stage I Closing;
(b) Subject to the satisfaction of the conditions precedent set forth
in Sections 6.1 and 6.3 hereof and subject to the terms and other conditions
hereinafter set forth, at the Stage II Closing, at the Investors' election, the
respective amount of Stage 2 Subordinated Notes and Stage 2 Warrants set forth
on Schedule 1, for an aggregate purchase price of $1,059,000 for the Stage II
----------
Closing.
3.2. CLOSING(S).
----------
(a) The closing(s) hereunder with respect to the transactions
contemplated by Sections 2 and 3.1(a) hereof (the "Stage 1 Closing") will take
place at the offices of Chu, Ring & Associates, 253 Summer Street, Boston,
Massachusetts, at 9:00 a.m. local time, on June 27, 1996, or at such other place
and time and on such other date as may be mutually agreed upon in writing by the
respective Investors and the Company (the "Stage 1 Closing Date").
(b) The closing(s) hereunder with respect to the transactions
contemplated by Sections 2 and 3.1(b) hereof (the "Stage 2 Closing") will take
place at the offices of Chu, Ring & Associates, 253 Summer Street, Boston,
Massachusetts, at 9:00 a.m. local time, or at such other place and time and on
such other date as may be mutually agreed upon in writing by the respective
Investors and the Company, on a mutually acceptable business day within 15 days
after the conditions set forth in Sections 6.1 and 6.3 have been satisfied or
waived in writing by the Investors, (the "Stage 2 Closing Date").
(c) At each Closing, the Company will, unless otherwise requested,
deliver to each Investor the Subordinated Notes and Warrants to be purchased by
such Investor, against payment of the purchase price in immediately available
funds or by cancellation of existing indebtedness, all as set forth on Schedule
--------
1.
- -
(d) Schedule 1 attached hereto shall be amended from time to time by
----------
adding thereto each of the Investors who executes a counterpart signature page
hereto (to the extent not so named).
4. REPRESENTATIONS AND WARRANTIES. In order to induce the Investors to enter
into this Agreement and to purchase the Subordinated Notes and Warrants to be
purchased by each Investor hereunder, the Company represents and warrants to
each Investor and agrees with each Investor as follows:
4.1. ORGANIZATION, STANDING, POWER, AUTHORITY, QUALIFICATION. The Company
------------ -------- ----- --------- -------------
is a duly organized and validly existing corporation in good standing under the
laws of the State of New York with corporate power and authority adequate for
(a) the execution and delivery
-
<PAGE>
-3-
of this Agreement and the performance of its obligations hereunder and under the
Related Agreements and (b) the carrying on-of the business conducted by it. The
Company has taken all corporate action necessary to authorize this Agreement and
the transactions contemplated hereby. The Company is duly qualified and in good
standing as a foreign corporation in each other jurisdiction in which such
qualification is required, and is duly authorized, qualified and licensed under
all laws, regulations ordinances or orders of public authorities, or otherwise,
to carry on its business in the places and in the manner conducted and to own
its properties and assets.
4.2. CAPITALIZATION. Immediately after the effective date of the Restated
--------------
Certificate of Incorporation (but before giving effect to the Closing(s)), the
authorized capital stock of the Company will consist of 3,500,000 shares of
Common Stock, par value $.10 per share ("Common Stock"), 434,100 shares of which
are issued and outstanding and 325,000 shares, 1,000 shares and 50,000 shares
have been duly reserved for issuance pursuant to the Company's Stock Option
Plan, Management Stock Bonus Plan and Directors' Stock Option Plan,
respectively, 509,258 shares of Series A Convertible Preferred Stock,
par value $.10 per share, all of which are issued and outstanding and held of
record by Kopin Corporation ("Kopin"), 185,185 shares of Series B Convertible
Preferred Stock, par value $.10 per share, all of which are issued and
outstanding and held of record by Kopin, and 233,333 shares of Series C
Convertible Preferred Stock, 233,333 shares of which are issued and outstanding.
Attached as Schedule 4.2 is a list of (i) all holders of capital stock of the
------------
Company, including the number of shares of capital stock held by each such
holder, and (ii) all outstanding warrants, options, agreements, convertible
securities or other commitments pursuant to which the Company is or may become
obligated to issue (or as to which it has reserved for issuance) any shares of
its capital stock or other securities of the Company, which names all persons
entitled to receive such shares or other securities (and/or states their
respective positions at the Company) and the shares or other securities required
to be issued thereunder. All such holders are parties to the Shareholders
Agreement. All of the issued and outstanding shares of the capital stock of the
Company have been duly authorized and validly issued in compliance with all
applicable provisions of the Securities Act of 1933, as amended (the "Securities
Act") and applicable state "blue sky" laws and regulations, and are fully paid,
non-assessable, and subject to no liens or restrictions on transfer of any kind
except restrictions on transfer imposed by applicable securities laws and as
contemplated under the Series A Preferred Stock Agreements, the Series B
Preferred Stock Agreements and the Series C Preferred Stock Agreements. The
Company does not have outstanding, except as contemplated by this Agreement and
the Related Agreements and disclosed herein or herewith, any rights (preemptive
or other) to subscribe for or to purchase, or any warrants or options for the
purchase of, or any agreements, understandings or arrangements providing for or
other obligations requiring the issuance (contingent or other) of, or any calls,
commitments or claims of any character relating to, any shares of any class of
its capital stock or any securities convertible into or exchangeable for any
such stock. The Company is not subject to any obligations (contingent or other)
to repurchase or otherwise acquire or rescind the sale of any shares of any
class of its stock or any securities, rights or options related thereto.
<PAGE>
-4-
4.3. GOVERNING DOCUMENTS. The copies of the Restated Certificate of
--------- ---------
Incorporation and By-Laws of the Company as currently in effect which have
heretofore been delivered to each of the Investors are true, complete and
correct.
4.4. FINANCIAL INFORMATION. The Company's balance sheet as at April 30,
--------- -----------
1996 and statement for operations for the three months then ended (unaudited),
previously delivered to each of the Investors, fairly present the Company's
financial condition as at such date and the Company's results of operations for
the period then ended. Except as disclosed on Schedule 4.4 to the
------------
Board of Directors of the Company [or the Investors], there has been no material
adverse change since April 30, 1996, in the business, operations, assets,
prospects or condition (financial or otherwise) of the Company or its Business
other than in the ordinary course of business.
4.5. ENFORCEABILITY OF AGREEMENTS. The Company has duly taken all
-------------- -- ----------
corporate action necessary to authorize the execution and delivery of this
Agreement and the performance of this Agreement and each of the Related
Agreements. This Agreement and each of the Related Agreements constitutes the
valid and binding agreement of the Company, enforceable against the Company in
accordance with its terms, except to the extent enforcement thereof may be
limited by insolvency, bankruptcy and similar laws affecting generally the
enforcement of contractual rights and by the discretionary nature of equitable
remedies.
4.6. NO VIOLATION; NO DEFAULTS. Neither the execution nor delivery of
-- --------- -- --------
this Agreement, nor the consummation of any transaction contemplated hereby or
by any of the Related Agreements, including without limitation the issuance and
sale of the Subordinated Notes and Warrants as provided herein, has constituted
or resulted in or will constitute or result in a breach of the provisions of any
mortgage, lease, license or other instrument, contract or agreement to which the
Company is a party or by which it is bound, or the charter or by-laws of the
Company or the violation of any judgment, decree, law or governmental or
administrative order, rule or regulation which, singly or in the aggregate, may
have any material adverse effect on the business, operations, assets, prospects
or condition (financial or otherwise) of the Company. Except as disclosed on
Schedule 4.6, the Company is not in default under any provision of its charter,
- ------------
by-laws, or under any provision of any mortgage, lease, license or other
instrument, contract or agreement to which it is a party or by which it is bound
or of any law, ordinance, approval, rule or regulation or any terms of any
applicable order, judgment or decree of any court, arbitrator or governmental or
administrative authority which, singly or in the aggregate, may have any
material adverse effect on the business, operation, assets, prospects or
condition (financial or otherwise) of the Company.
4.7. BROKERS' FEES. There are no brokers', finders', or similar fees due
-------- ----
from the Company in respect of the transactions contemplated by this Agreement
or any of the Related Agreements.
4.8. ABSENCE OF UNDISCLOSED LIABILITIES. Except as disclosed in Schedule
------- -- ----------- ----------- --------
4.8 or in the financial statements referred to in Section 4.4 hereof, or arising
- ---
in the ordinary course of business and for obligations created pursuant to this
Agreement and the Related Agreements, as of the Closing Date, the Company will
have no material liabilities (fixed or
<PAGE>
-5-
contingent, including without limitation any liabilities for money borrowed or
any tax liabilities due or to become due) and will be subject to no material
obligations under any contract or commitment of any kind.
4.9. LITIGATION. Except as disclosed on Schedule 4.9, there is neither
---------- ------------
pending nor, to the Company's knowledge and belief, threatened any action, suit,
proceeding or claim, or any basis therefor, to which the Company is or may be
named as a party or its property is or may be subject or which calls into
question any of the transactions contemplated by this Agreement.
4.10. CONSENTS. Except as disclosed on Schedule 4.10, no
-------- --------------
consent, approval or authorization of, or filing with, any governmental
authority is required in connection with the Company's valid execution, delivery
or performance of this Agreement and the Related Agreements, or the consummation
of any other transaction to be consummated at the Closing.
4.11. TRADEMARKS, LICENSES, ETC. Except as disclosed on Schedule 4.11 and
---------- -------- --- -------- ----
to the extent of the collateral security interest of Kopin therein, the Company
has or has the right to use all patents, patent applications, trademarks,
trademark rights, trade names, trade name rights, copyrights, licenses, trade
secrets, permits, authorizations and other rights, as are necessary for the
conduct of its business, all of which are in full force and effect, and the
Company is in substantial compliance with the foregoing without any infringement
of, adverse claim in respect of or known conflict with the valid rights of
others which could affect or impair in a material manner the business or assets
or financial condition of the Company. The Company has previously delivered to
each of the Investors a schedule listing all material patents, patent
applications, licenses, copyrights and similar intellectual property rights of
the Company. All material items of intellectual property used by the Company's
business are or will be made subject to patent, copyright, trade secret or other
appropriate legal protection and the Company is under no obligation to
compensate any other Person for the use thereof. The Company has complied with
all of its obligations of confidentiality in respect of the claimed trade
secrets or proprietary information of others and knows of no violation of such
obligations of confidentiality as are owed to the Company. No employee, agent
or consultant of the Company is subject to confidentiality restrictions in favor
of any third person the breach of which could subject the Company to any
material liability. Each of the Company's key employees has executed and
delivered an Employee Proprietary Rights and Nondisclosure Agreement in
substantially the form previously delivered to Kopin in connection with the
Series A Preferred Stock Agreements.
4.12. FOUNDER. Travers is of sound mind and body and mentally and
-------
physically capable of fulfilling his obligations under the Employment Agreement.
4.13. PROCEEDS. All cash proceeds from the sale of the Subordinated Notes
--------
and Warrants will be used for working capital purposes including payment of
trade debt.
4.14. REGISTRATION RIGHTS. Except as provided for in the Series A
------------ ------
Securities Purchase Agreement, the Series B Securities Purchase Agreement, the
Series C Securities Purchase Agreement and the Registration Rights Agreement and
as contemplated hereby,
<PAGE>
-6-
the Company is under no obligation to register under the Securities Act any of
its currently outstanding securities or any of its securities which may
hereafter be issued.
4.15. SUBSIDIARIES; TITLE TO PROPERTIES; LIENS AND ENCUMBRANCES;
------------ ----- -- ---------- ----- --- ------------
INSURANCE. Except as set forth on Schedule 4.15 hereto, the Company has no
- --------- -------------
subsidiary and owns no security issued by or interest in any other corporation,
partnership or other organization. The Company has valid title to and ownership
of all the properties and assets purported to be owned by it, free from all
mortgages, pledges, liens, security interests, conditional sale agreements,
encumbrances or charges, except such as are described on Schedule 4.15 hereto.
-------- ----
The Company enjoys peaceful and undisturbed possession under all leases under
which it is operating and all such leases are valid and subsisting and in full
force and effect. The Company maintains those insurances (including product
liability insurance) and in the amounts set forth on Schedule 4.15 hereto.
-------- ----
4.16. ENVIRONMENTAL COMPLIANCE. The Company has taken all necessary steps
------------- ----------
to investigate its usage of its properties and its operations conducted thereon
and, based upon such diligent investigation, has determined that:
(a) none of the Company or, to the best of its knowledge, any operator
of its properties is in violation, or alleged violation, of any judgment,
decree, order, law, license, rule or regulation pertaining to environmental
matters, including without limitation those arising under the Resource
Conservation and Recovery Act ("RCRA"), the Comprehensive Environmental
Response, Compensation and Liability Act of 1980 as amended ("CERCLA"), the
Superfund Amendments and Reauthorization Act of 1986 ("SARA"), the Federal Clean
Water Act, the Federal Clean Air Act, the Toxic Substances Control Act, or any
state or local statute, regulation, ordinance, order or decree relating to
health, safety or the environment (hereinafter "Environmental Laws"), which
violation would have a material adverse effect on the environment or the
business, assets or financial condition of the Company;
(b) the Company has not received notice from any third party including
without limitation any federal, state or local governmental authority, (i) that
the Company or any predecessor in interest has been identified by the United
States Environmental Protection Agency ("EPA") as a potentially responsible
party under CERCLA with respect to a site listed on the National Priorities
List, 40 C.F.R. Part 300 Appendix B (1986); (ii) that any hazardous waste as
defined by 42 U.S.C. (S)6903(5), any hazardous substances as defined by 42
U.S.C. (S)9601(14), any pollutant or contaminant as defined by 42 U.S.C.
(S)9601(33) and any toxic substance, oil or hazardous materials or other
chemicals or substances regulated by any Environmental Laws ("Hazardous
Substances") which any one of them has generated, transported or disposed of has
been found at any site at which a federal, state or local agency or other third
party has conducted or has ordered that the Company or any predecessor in
interest conduct a remedial investigation, removal or other response action
pursuant to any Environmental Law; or (iii) that any of them is or shall be a
named party to any claim, action, cause of action, complaint (contingent or
otherwise) legal or administrative proceeding arising out of any third party's
incurrence of costs, expenses, losses or damages of any kind whatsoever in
connection with the release of Hazardous Substances;
<PAGE>
-7-
(c) except as set forth in Schedule 4.16, to the best of the Company's
-------- ----
knowledge: (i) no portion of the Company's properties has been used for the
handling, manufacturing, processing, storage or disposal of Hazardous Substances
except in accordance with applicable Environmental Laws; and no underground tank
or other underground storage receptacle for Hazardous Substances is located on
such properties; (ii) in the course of any activities conducted by the Company
or operators of its properties, no Hazardous Substances have been generated or
are being used on such properties except in accordance with applicable
Environmental Laws; (iii) there have been no releases (i.e. any past or present
- -
releasing, spilling, leaking, pumping, pouring, emitting, emptying, discharging,
injecting, escaping, disposing or dumping) or threatened releases of Hazardous
Substances on, upon, into or from the properties of the Company, which releases
would have a material adverse effect on the value of such properties or adjacent
properties or the environment; (iv) to the best of the Company's knowledge,
there have been no releases on, upon, from or into any real property in the
vicinity of the real properties of the Company which, through soil or ground
water contamination, may have come to be located on, and which would have a
material adverse effect on the value of, the properties of the Company; and (v)
in addition, any Hazardous Substances that have been generated on the properties
of the Company, have been transported offsite only by carriers having an
identification number issued by the EPA and treated or disposed of only by
treatment or disposal facilities maintaining valid permits as required under
applicable Environmental Laws, which transporters and facilities have been and
are, to the best of the Company's knowledge, operating in compliance with such
permits and applicable Environmental Laws; and
(d) to the best of the Company's knowledge, none of the properties of
the Company are or shall be subject to any applicable environmental cleanup
responsibility law or environmental restrictive transfer law or regulation by
virtue of the transactions set forth herein and contemplated hereby.
4.17. TAXES. The Company and its Predecessor have, to the best of the
-----
Company's knowledge, accurately prepared and timely filed all federal, state and
other tax returns required by law to be filed by each of them, and all taxes
shown to be due and all additional assessments have been paid or provision made
therefore. There are no transfer, issuance or similar taxes imposed by law in
connection with the issuance, sale or delivery of the Subordinated Notes or
Warrants.
4.18. OFFERING. Subject to the truth and accuracy of the representations
--------
of each of the Investors set forth in Section 5 hereof, the offer, sale and
issuance of the Subordinated Notes and Warrants as contemplated by this
Agreement are exempt from the registration requirements of the Securities Act,
and neither the Company nor any one acting on its behalf will take any action
hereafter that would cause the loss of such exemption. The Company has complied
and will comply with all applicable state "blue sky" or securities laws in
connection with the offer, sale and issuance of the Subordinated Notes and
Warrants as contemplated by this Agreement.
<PAGE>
-8-
4.19. DISCLOSURE. Neither this Agreement nor any of the Related
----------
Agreements contains any untrue statement of a material fact or omits to state a
material fact necessary in order to make the statements contained herein or
therein misleading in the light of the circumstances under which they were made.
There is no fact known to the Company which materially adversely affects, or in
the future is likely to materially adversely affect, the business, operations,
affairs, prospects, condition, properties or assets of the Company which has not
been set forth in this Agreement (including the exhibits and schedules hereto),
in the other documents, certificates, instruments or statements furnished to
each of the Investors by or on behalf of the Company or in reports to the Board
of Directors.
5. INVESTOR REPRESENTATIONS. Each of the Investors represents and warrants to
the Company that:
5.1. That he or it has received and carefully reviewed descriptive
memoranda relating to the Company and any other materials relating thereto that
he has requested.
5.2. That no person or entity, other than the Company or its authorized
representatives, has offered the Subordinated Notes or Warrants to the
undersigned.
5.3. That he or it has such knowledge and experience in financial and
business matters that he or it is capable of evaluating the merits and risks of
an investment in the Company, or he and his or its financial and investment
advisors together have such knowledge and experience in financial and business
matters that they are capable of evaluating the merits and risks of an
investment in the Company.
5.4. That (i) it has been called to his or its attention in connection
with his or its investment in the Company that such investment is speculative in
nature and involves a high degree of risk, (ii) he or it is aware that the
Company is in the start-up stage and thus has a limited operating history, (iii)
he or it is aware that the financial and working capital position of the Company
has deteriorated and sales have declined significantly in the current fiscal
year, that a substantial portion of the proceeds hereof will be used to pay
trade debt and secured debt and that the Company's trade debt exceeds the amount
of the proceeds from the sale of the Subordinated Notes and Warrants and the
Company's current cash on hand, (iv) he or it is aware that to the extent that
the net proceeds of this offering and internally generated funds are
insufficient to fund the Company's operating requirements, it may be necessary
for the Company to seek additional funding, with no assurance that such
financing will be available on acceptable terms or at all, (v) he or it is aware
that if additional funds are raised by issuing equity securities, dilution to
the existing stockholders may result and (vi) he or it is aware that if adequate
funds are not available, the Company's business would be adversely affected, and
as a result, the Company may not be able to continue its operations.
5.5. It is acquiring the Subordinated Notes and Warrants for investment,
and not with a view to selling or otherwise distributing any thereof in
violation of the Securities Act; provided, however, that nothing contained
-------- -------
herein shall prevent any Investor from requesting that the Subordinated Notes
and Warrants be registered in the name of its nominee or transferring the
Subordinated Notes and Warrants in compliance with applicable laws.
<PAGE>
-9-
5.6. He and his or its representatives have had an opportunity to meet with
the officers of the Company to discuss such matters as such Investor has elected
to review, and that any questions regarding the Company and its business have
been answered to the full satisfaction of the undersigned.]
5.7. He or it is an "accredited investor" as defined in Regulation D under
the Securities Act.
5.8. That he or it understands that no federal or state agency has passed
upon or made any recommendation or endorsement of an investment in the
Subordinated Notes and Warrants.
5.9. That he or it will notify the Company immediately, and in any event
prior to the date this agreement is accepted by the Company, if any event occurs
which would materially and adversely affect any of the above representations or
warranties.
5.10. He or it has taken all necessary action to authorize its execution,
delivery and performance of this Agreement and the other Related Agreements to
which it is or may become a party. This Agreement constitutes, and each of the
Related Agreements to which it is a party will constitute, upon execution and
delivery thereof at the Closing, its legal, valid and binding agreement.
5.11. He or it has not retained, utilized or been represented by any
broker or finder in connection with the transactions contemplated by this
Agreement.
5.12. Each Investor who is also a Series C Investor hereby certifies that
the information contained in the Offeree Questionnaire that he or it delivered
in connection with the Series C Purchase Agreement is true and correct as of the
date hereof.
6. CONDITIONS PRECEDENT.
6.1. CONDITIONS PRECEDENT TO EACH CLOSING. The purchase by the Investors
------------------------------------
of the Subordinated Notes and Warrants at each Closing is subject to the
Company's compliance with its agreements herein and to the satisfaction, on or
prior to each Closing Date, of the following conditions precedent:
(A) LEGALITY; GOVERNMENTAL AUTHORIZATIONS. The purchase of and
-------- ------------ --------------
payment for the Subordinated Notes and Warrants to be purchased by each of the
Investors shall not be prohibited by any law or governmental order or
regulation, and shall not subject the Investor to any penalty, tax, liability or
other onerous condition. All necessary consents, approvals, licenses, permits,
orders and authorizations of, or registrations, declarations and filings with,
any governmental or administrative agency or of any other Person with respect to
any of the transactions contemplated hereby or by the Related Agreements shall
have been duly obtained or made and shall be in full force and effect. True and
complete copies of each of the foregoing as in effect shall have been furnished
to each Investor.
<PAGE>
-10-
(B) NO CHANGE IN LAW, ETC. No legislation, order, rule, ruling or
-- ------ -- --- ---
regulation shall have been enacted or made by or on behalf of any governmental
body, department or agency, nor shall any investigation by any governmental
authority or administrative body have been commenced, nor shall any decision of
any court of competent jurisdiction have been rendered which in the judgment of
the Investor would materially and adversely affect, restrain, prevent or change
the transactions contemplated by this Agreement or the Related Agreements or
materially and adversely affect the business, operations, assets, prospects or
condition (financial or otherwise) of the Company.
(C) PROPER PROCEEDINGS. All necessary and proper proceedings shall
------ -----------
have been taken by the Company to authorize the execution, delivery and
performance of each of this Agreement and the Related Agreements and of each of
the transactions contemplated hereby and thereby.
(D) GENERAL. All instruments and legal, governmental, administrative
-------
and corporate proceedings in connection with the transactions contemplated by
this Agreement and the Related Agreements shall be satisfactory in form and
substance to the Investor, and each Investor shall have received counterpart
originals, or certified or other copies of all documents, including without
limitation records of corporate or other proceedings and opinions of counsel,
which it may have reasonably requested in connection therewith.
(E) RESTATED CERTIFICATE OF INCORPORATION. The Restated Certificate
-------------------- -- -------------
of Incorporation attached hereto as Exhibit 6.1(e) shall have been approved by
--------------
resolutions duly adopted by the Company's shareholders and its board of
directors and shall have been filed by the office of the Secretary of State of
the State of New York.
(F) SERIES A PREFERRED STOCK AGREEMENTS, SERIES B PREFERRED STOCK
-------------------------------------------------------------
AGREEMENTS, AND SERIES C PREFERRED STOCK AGREEMENTS. Each of the Series A
- ---------- --- ------ -----------------------------
Preferred Stock Agreements, the Series B Preferred Stock Agreements and the
Series C Preferred Stock Agreements (as modified hereby) shall be in full force
and effect.
6.2. CONDITIONS PRECEDENT TO STAGE 1 CLOSING. In addition to the
----------------------------------------
satisfaction of the conditions set forth in Section 6.1 above, the purchase by
each Investor of the Stage 1 Subordinated Notes and Stage 1 Warrants at the
Stage 1 Closing is subject to the satisfaction of the following conditions
precedent:
(A) LEGAL OPINION. Each Investor shall have received a favorable
----- -------
legal opinion from Underberg & Kessler substantially in the form of Exhibit
-------
6.2(a) hereto.
- ------
(B) REPRESENTATIONS AND WARRANTIES; OFFICERS' CERTIFICATES. The
--------------- --- ---------- -------- ------------
representations and warranties contained or incorporated by reference herein
shall be true and correct in all material respects on and as of the Stage 1
Closing Date with the same force and effect as though made on and as of the
Stage 1 Closing Date, both before and after giving effect to the sale of the
Stage 1 Subordinated Notes and Stage 1 Warrants; and each Investor shall have
received on the Stage 1 Closing Date a certificate to these effects
<PAGE>
-11-
signed by the Chief Executive Officer of the Company and a certificate
as to the matters represented and warranted in Section 4.12 signed by Travers.
(C) ELECTION OF CHIEF EXECUTIVE OFFICER. Paul Travers shall have been
------------------------------------
elected Chairman and Chief Executive Officer of the Company.
(D) EMPLOYMENT OF MARTY STRAYER. Marty Strayer shall have been
----------------------------
elected and agreed to serve as Chief Operating Officer and President of the
Company, with responsibility for overall operations of the Company on a day to
day basis, on a full-time basis.
(E) REVESTING OF TRAVERS SHARES. Paul Travers shall have agreed to
---------------------------
the revesting of certain of his shares of common stock in accordance with the
Letter Agreement in substantially the form of Exhibit 6.2(e) hereto.
--------------
(F) ADMINISTRATIVE SERVICES AGREEMENT. Kopin Corporation and the
----------------------------------
Company shall have entered into an Administrative Services Agreement in
substantially the form attached hereto as Exhibit 6.2(f).
--------------
(G) SECURITY AGREEMENT. The Company and Kopin Corporation, as agent
-------------------
for itself and the other Investors, shall have entered into a Security Agreement
in substantially the form attached hereto as Exhibit 6.2(g).
--------------
6.3. CONDITIONS PRECEDENT TO STAGE 2 CLOSING. In addition to the
----------------------------------------
satisfaction of the conditions set forth in Section 6.1 above, the purchase by
the Investors of the Stage 2 Subordinated Notes and Stage 2 Warrants at the
Stage 2 Closing is subject to the satisfaction of the following conditions
precedent:
(A) MILESTONES. The Company's President and Chief Executive Officer
-----------
shall have delivered a written notice to the Investors certifying that the
milestones set forth in Schedule 6.3 hereto have been reached.
------------
(B) APPROVAL OF MAJORITY OF THE INVESTORS. The holders of not less
--------------------------------------
than 51% of the Stage 1 Subordinated Notes and Stage 1 Warrants shall have
elected to exercise the option to proceed with the Stage 2 Closing.
(C) REPRESENTATIONS AND WARRANTIES; OFFICERS' CERTIFICATES. The
--------------- --- ---------- -------- ------------
representations and warranties contained or incorporated by reference herein
shall be true and correct in all material respects on and as of the Stage 2
Closing Date with the same force and effect as though made on and as of the
Stage 2 Closing Date, both before and after giving effect to the sale of the
Subordinated Notes and Warrants; and each Investor shall have received on the
Stage 2 Closing Date a certificate to these effects signed by the President of
the Company and a certificate as to the matters represented and warranted in
Section 4.12 signed by Travers.
7. COVENANTS. The covenants of the Company set forth in Section 7 of the
Series A Securities Purchase Agreement with the Investor therein are
incorporated herein by
<PAGE>
-12-
reference with the same force and effect with respect to the obligations of the
Company and the rights of the Investors.
8. TERMINATION OF SECTION 8 AND SECTION 9 OF SERIES C STOCK PURCHASE
AGREEMENT. The Company and each of the Investors hereby agree that Section 8
and Section 9 of the Series C Stock Purchase Agreement are hereby terminated and
of no further force and effect.
9. OPERATING COVENANTS. The Company covenants that so long as any of the
Subordinated Notes and Warrants remain outstanding it will comply with the
operational, administrative and reporting obligations set forth on Exhibit 9
---------
hereto and incorporated herein by reference.
10. AMENDMENTS TO SERIES PREFERRED STOCK AGREEMENTS. The Company, Travers,
Travers Family Limited Liability Company and the Investors hereby agree to amend
the Series Preferred Stock Agreements as follows:
10.1. Section 4 of the Shareholders Agreement is hereby deleted and
replaced in its entirety with the revised Section 4 on Exhibit 10.1 hereto.
10.2. Section 8.9 of the Shareholders Agreement is hereby deleted and
replaced its entirety to read as follows:
"No waiver, amendment, modification or termination of this Agreement shall
be valid unless the same is in writing and signed by (i) the Company, (ii)
those Shareholders holding not less than fifty-one percent (51%) of all
shares of Common Stock issued and issuable upon conversion of the Preferred
Stock and the exercise of the Common Stock Purchase Warrants dated as of
June , 1996 held of record at such time (the "Common Stock Purchase
Warrants"), and (iii) those Shareholders holding not less than fifty-one
percent (51%) of all shares of Common Stock issued and outstanding and
Common Stock issuable upon exercise of warrants (other than the Preferred
Stock and Common Stock Purchase Warrants), options or other rights to
acquire Common Stock held of record at such time."
10.3. Section 3 of the First Refusal Agreement is hereby deleted and
replaced in its entirety with the revised Section 3 on Exhibit 10.3 hereto.
10.4. The definition of "Holders" in the Registration Rights Agreement is
hereby amended to include each of the Investors.
10.5. By executing and delivering this Agreement, the Company and each
Investor acknowledges and agrees that each Investor is being made a party to,
and is bound by, the respective provisions of the Shareholders Agreement, First
Refusal Agreement and the Registration Rights Agreement (as amended herein) as
if it were an Investor party thereto.
11. REMEDIES.
<PAGE>
-13-
11.1. REMEDIES. If any party shall fail to perform or observe any of the
--------
covenants, agreements or provisions set forth or incorporated by reference in
this Agreement or in any of the Related Agreements, then and in each and every
such case the other party may proceed to enforce performance of such obligations
in such manner as it may elect and may proceed to protect and enforce its rights
by suit in equity, action at law and/or other appropriate proceeding for
performance of such obligations.
11.2. COURSE OF DEALING. No course of dealing between the Company on the
------ -- -------
one hand, and any Investor or any holder of the Subordinated Notes or Warrants,
on the other hand, shall operate as a waiver of any rights under this Agreement
or any Related Agreement. A waiver on any one occasion shall not be construed
as a bar to or waiver of any right or remedy on any other occasion. No waiver
or statement of satisfactory cure or consent shall be binding upon one party or
any holder of any Subordinated Notes or Warrants unless it is in writing and
signed by the party to be changed.
11.3. WAIVERS. Each party hereby waives, to the extent not prohibited by
-------
applicable law, (a) all presentments, demands for performance, notices of
nonperformance (except to the extent required by the provisions hereof) and (b)
any requirement of diligence or promptness on the part of any other party under
any Subordinated Notes or Warrants in the enforcement of its rights under the
provisions of this Agreement.
11.4. EQUITABLE REMEDIES. The parties to this Agreement hereby
--------- --------
acknowledge that monetary damages are an inadequate remedy for breach of the
covenants and provisions contained in this Agreement or in any Related
Agreement; therefore, it is agreed that each of such covenants of one party and
provisions shall be enforceable by specific performance, including all forms of
injunctive relief. Each party hereby waives any defense based on the adequacy
of any remedies at law.
12. PAYMENT ON SUBORDINATED NOTES AND WARRANTS; TRANSFER; LEGENDS
12.1. PAYMENT. All payments made by the Company in respect of any
-------
Subordinated Notes and Warrants shall be made in immediately available funds in
lawful money of the United States for credit, not later than 12:00 noon, Boston
time, to the account of the respective Investor and shall be accompanied by
sufficient information to identify the source and application thereof, or in any
event by such other reasonable method or at such other address, as the
respective Investor shall have from time to time notified the Company thereof.
12.2. TRANSFER OF SUBORDINATED NOTES AND WARRANTS. If, at any time of any
-------- -- -------------------------------
exercise, transfer (other than a conversion or transfer not involving a change
in the beneficial ownership of such securities) or surrender for exchange of any
Subordinated Notes or Warrants or any securities issued upon exchange or
conversion, or in replacement thereof (or in respect of such securities), such
securities shall not be registered under the Securities Act or qualified under
any applicable state securities law, the Company may require, as a condition of
allowing such conversion, transfer or exchange, that the holder or
<PAGE>
-14-
transferee of such securities, as the case may be, furnish to the Company such
information as, in the reasonable opinion of counsel for the Company, is
necessary in order to establish that such exercise, transfer or exchange may be
made without registration under the Securities Act or qualification under such
state securities law; provided, however, that nothing contained in this Section
--------- --------
12.2 shall relieve the Company from complying with the provisions of Section 8
of the Series A Securities Purchase Agreement, as amended hereby, or any
provision of the Restated Certificate of Incorporation.
12.3. LEGENDS. To the extent applicable, each certificate or other
-------
document evidencing any of the Subordinated Notes and Warrants to be purchased
and sold pursuant to this Agreement or any Common Stock issued upon exercise of
the Warrants shall be endorsed with the legends set forth below, and each
Investor covenants that, except to the extent such restrictions are waived by
the Company, it shall not transfer the shares represented by any such
certificate without complying with the restrictions on transfer described in the
legends endorsed on such certificate:
(a) The following legend under the Securities Act:
"THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD,
TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED ABSENT AN EFFECTIVE
REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH RULE 144
PROMULGATED UNDER SUCH ACT, OR UNLESS THE COMPANY HAS RECEIVED AN
OPINION OF COUNSEL, IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO
THE COMPANY AND ITS COUNSEL AND FROM ATTORNEYS REASONABLY ACCEPTABLE
TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT
REQUIRED."
(b) If required by the authorities of any state in connection with the
issuance or sale of the Subordinated Notes or Warrants or the Common Stock
issued upon exercise of the Warrants, the legend required by such state
authority.
12.4. REMOVAL OF LEGENDS.
------- -- -------
(a) Any legend endorsed on a certificate pursuant to Section 12.3(a)
hereof shall be removed (i) if the Subordinated Notes and Warrants to be
-
purchased and sold pursuant to this Agreement or Common Stock issued upon
exercise of the Warrants represented by such certificate shall have been
effectively registered under the Securities Act, (ii) if such securities are
--
being transferred in compliance with Rule 144 promulgated under the Securities
Act, or (iii) if the holder of such securities shall have provided the Company
---
with an opinion of counsel, in form and substance reasonably acceptable to the
Company and its counsel and from attorneys reasonably acceptable to the Company
and its counsel, stating that the proposed sale, transfer or assignment of such
shares may be made without registration.
<PAGE>
-15-
(b) Any legend endorsed on a certificate pursuant to Section 12.3(b)
hereof shall be removed if the Company receives an order of the appropriate
state authority authorizing such removal or if the holder of Subordinated Notes
and Warrants to be purchased and sold pursuant to this Agreement or Common Stock
issued upon exercise of the Warrants provides the Company with an opinion of
counsel, in form and substance reasonably acceptable to the Company and its
counsel and from attorneys reasonably acceptable to the Company and its counsel,
stating that such legend may be removed.
13. EXPENSES, ETC. Whether or not the transactions contemplated by this
Agreement and the Related Agreements shall be consummated, each party agrees to
pay and be responsible for the respective expenses incurred by it in connection
herewith.
14. NOTICES. All notices and other communications pursuant to this Agreement
shall be in writing, either delivered in hand or sent by first-class mail,
postage prepaid, or sent by telex, telecopier, facsimile machine or telegraph,
addressed as follows:
(a) if to the Company, at the address thereof set forth on the first
page hereof, or at such other address as shall have been furnished to the
Investor in writing by the Company with a copy to Underberg & Kessler, 1800
Chase Square, Rochester, New York 14604, Attention: Robert F. Mechur,
Esq.;
(b) if to the Investors, at the address thereof set forth next to the
respective Investor's name on Schedule 1 hereto or at such other address as
----------
shall have been furnished to the Company in writing by the Investor with a
copy to John H. Chu, Esq., c/o Chu, Ring & Associates, 253 Summer Street,
Boston, MA 02210.
Any notice or other communication pursuant to this Agreement shall be
deemed to have been duly given or made and to have become effective (i) when
-
delivered in hand to the party to which it was directed, (ii) if sent by telex,
--
telecopier, facsimile machine or telegraph and properly addressed in accordance
with the foregoing provisions of this Section 14, when received by the
addressee, or (iii) if sent by first-class mail, postage prepaid, and properly
---
addressed in accordance with the foregoing provisions of this Section 14, (A)
-
when received by the addressee, or (B) on the third business day following the
-
day of dispatch thereof, whichever of (A) or (B) shall be the earlier.
- -
15. SURVIVAL AND TERMINATION OF COVENANTS. All covenants, agreements,
representations and warranties made herein or in any other document referred to
herein or delivered to the Investors pursuant hereto shall be deemed to have
been material and relied on by each of the Investors, notwithstanding any
investigation made by the Investors, and shall survive the execution and
delivery to the Investors hereof and of the Subordinated Notes and Warrants and
shall terminate only as follows: (a) upon the Company's Qualified Initial Public
-
Offering, except as to the covenants of the Company contained in Sections 7, 8,
and 9 hereof, the provisions of Section 8 of the Series A Securities Purchase
Agreement and Sections 13 and 15 hereof; or (b) as to any Investor, if such
-
Investor no longer holds any Subordinated Notes and Warrants or any Common
Stock, this Agreement shall terminate in its entirety except for the provisions
of Sections 13 and 15 hereof.
<PAGE>
-16-
16. AMENDMENTS AND WAIVERS. Except as otherwise expressly required by any
other provisions of this Agreement, none of the terms or provisions contained in
this Agreement, and none of the agreements, obligations or covenants of the
Company contained in this Agreement or in any Related Agreement or in any of the
Series Preferred Stock Agreements to the extent that, as amended hereby, they
may affect, govern, or apply to the Subordinated Notes and Warrants, may be
amended, modified, supplemented, waived or terminated unless the Company and
Investors holding not less than sixty percent (60%) of the principal amount of
the Subordinated Notes and shares issued upon exercise of the Warrants shall
execute an instrument in writing agreeing or consenting to such amendment,
modification, supplement, waiver or termination.
17. MISCELLANEOUS. This Agreement and the Related Agreements set forth the
entire understanding of the parties hereto with respect to the transactions
contemplated hereby. The invalidity or unenforceability of any term or
provision hereof shall not affect the validity or enforceability of any other
term or provision hereof. The headings in this Agreement are for convenience of
reference only and shall not alter or otherwise affect the meaning hereof. This
Agreement is intended to take effect as a sealed instrument and may be executed
in any number of counterparts which together shall constitute one instrument and
shall be governed by and construed in accordance with the domestic substantive
laws of the State of New York without giving effect to any choice or conflict of
law provision or rule that would cause the application of the domestic
substantive laws of any other state, and shall bind and inure to the benefit of
the parties hereto and their respective successors and assigns.
18. WAIVER OF FIRST REFUSAL RIGHTS. By executing and delivering this
Agreement, except to the extent of his or its participation herein, each
Investor hereby irrevocably waives his or its rights under Section 3 of the
First Refusal Agreement (as amended herein) in respect of having a first option
(including written notice thereof) to purchase his or her or its Percentage
Entitlement of the Subordinated Notes and Warrants.
[remainder of page intentionally left blank]
<PAGE>
-17-
If the foregoing corresponds with your understanding of our agreement,
kindly sign this signature page and the accompanying copies thereof (which have
already been signed by the Company) in the appropriate space below and return
one counterpart of the same to the Company. This letter shall thereupon become
a binding agreement between you and the Company.
Very truly yours,
FORTE TECHNOLOGIES, INC.
By:________________________________
Title
FOR PURPOSES OF SECTION 10 ONLY:
___________________________________
Paul J. Travers
FOR PURPOSES OF SECTION 10 ONLY:
TRAVERS FAMILY LIMITED LIABILITY COMPANY
By:________________________________
Title
<PAGE>
-18-
ACCEPTED and AGREED TO:
KOPIN CORPORATION
By:_______________________________
Title
<PAGE>
-19-
ACCEPTED and AGREED TO:
BALDWIN AND LYONS INC.
By:_______________________________
Title
<PAGE>
-20-
ACCEPTED and AGREED TO:
SF PARTNERS I LIMITED PARTNERSHIP
By:_______________________________
Title
<PAGE>
-21-
ACCEPTED and AGREED TO:
NS ASSOCIATES INC.
By:_______________________________
Title
<PAGE>
-22-
ACCEPTED and AGREED TO:
JOHN D. WEIL, TRUSTEE, U/I/T 6-28-91
JOHN D. WEIL TRUST
By:_______________________________
Title
<PAGE>
-23-
ACCEPTED and AGREED TO:
DIAMOND CONSOLIDATED LIMITED PARTNERSHIP
By:_______________________________
Title
<PAGE>
-24-
ACCEPTED and AGREED TO:
DIAMOND FAMILY FOUNDATION
By:_______________________________
Title
<PAGE>
-25-
ACCEPTED and AGREED TO:
W.J. PRATT INVESTMENT ASSOCIATES
By:_______________________________
Title
<PAGE>
-26-
ACCEPTED and AGREED TO:
_______________________________
Michael Wall
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-START> JAN-01-1996
<PERIOD-END> JUN-29-1996
<CASH> 18,735,343
<SECURITIES> 13,288,442
<RECEIVABLES> 8,155,535
<ALLOWANCES> 0
<INVENTORY> 6,851,140
<CURRENT-ASSETS> 48,404,962
<PP&E> 22,012,766
<DEPRECIATION> 10,634,744
<TOTAL-ASSETS> 65,853,327
<CURRENT-LIABILITIES> 12,860,639
<BONDS> 2,291,898
0
0
<COMMON> 109,188
<OTHER-SE> 49,221,362
<TOTAL-LIABILITY-AND-EQUITY> 65,853,327
<SALES> 5,626,256
<TOTAL-REVENUES> 10,057,809
<CGS> 4,933,070
<TOTAL-COSTS> 14,136,398
<OTHER-EXPENSES> 4,990,412<F1>
<LOSS-PROVISION> 24,000
<INTEREST-EXPENSE> 217,518
<INCOME-PRETAX> (12,614,092)
<INCOME-TAX> 0
<INCOME-CONTINUING> (12,614,092)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (12,614,092)
<EPS-PRIMARY> (1.16)
<EPS-DILUTED> (1.16)
<FN>
<F1>Non-recurring charge of $4,990,412 included a write-down associated with the
initial adoption of SFAS No. 121, the expensing of purchased technology, and
the write-off of certain previously deferred expenses.
</FN>
</TABLE>
